Jan 20 2010
Neomend, 
      Inc., an innovator in sealant and adhesion-prevention products for the 
      surgical marketplace, announced it has received premarket approval from 
      the U.S. Food and Drug Administration (FDA) for the company’s ProGEL™ 
      Pleural Air Leak Sealant.
    
“We are very excited to receive this approval and be in a position to 
      provide this unique technology to the surgeons and patients who greatly 
      need it”
    
      ProGEL is a hydrogel polymer sealant consisting of two components: human 
      serum albumin and a cross-linking component of polyethylene glycol. When 
      they are mixed together, a rapid reaction occurs that creates a hydrogel 
      matrix which results in the formation of a strong, adherent and flexible 
      seal.
    
    
      ProGEL is intended for application to visceral pleura during an open 
      thoracotomy after standard visceral pleural closure with, for example, 
      sutures or staples, of visible air leaks (≥2 mm) incurred during open 
      resection of lung parenchyma. ProGELTM Pleural Air Leak 
      Sealant is the only such product with this specific approved indication 
      in the United States.
    
    
      “We are very excited to receive this approval and be in a position to 
      provide this unique technology to the surgeons and patients who greatly 
      need it,” said David Renzi, the company’s President and CEO. “This 
      technology has also been shown to reduce hospital stay days, a benefit 
      that can significantly reduce the total cost of these procedures to the 
      hospital. Neomend will move quickly to bring this important product to 
      market.”
    
    
      FDA approval came following a multi-center clinical study on the device 
      that encompassed 161 patients in five institutions: Mayo Clinic, 
      Cedars-Sinai Medical Center, Duke University, MD Anderson Cancer Center, 
      and the University of Washington.
    
    
      ProGEL was shown to be 77% effective in sealing air leaks 
      intra-operatively, compared to 16% for the control group. The device led 
      to a statistically significant reduction in both intraoperative air 
      leaks and hospital stay of nearly two days.
    
    
      The newly available device addresses a current, unmet surgical need to 
      seal pleural air leaks incurred during lung surgery. The company 
      estimates approximately 150,000 lung resections are performed in the 
      United States every year. Intraoperative air leaks are a primary 
      complication of lung surgery and can lead to other complications such as 
      infections, pneumonia and extended hospitalization.
    
    Source: Neomend, 
      Inc.